Avai Bio, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Chris Winter
- Full Time Employees
- 1
- Sector
- Technology
- Industry
- Software - Application
- Address
- Sv. Stepono g. 27D-2 Vilnius NV Lithuania 89108
- IPO Date
- Apr 6, 2020
- CIK
- 0001740797
- Website
- avaibio.com
- Similar Companies
- Business
- Avant Technologies Inc. (OTCQB: AVAI) is an artificial intelligence technology company that acquires, creates, and develops advanced AI technologies and infrastructure solutions; provides information technology consulting services including full-stack software development, database management, data integration, project management, and cloud services; and offers AI platforms such as Avant! AI for natural language processing, computer vision, predictive analytics, and machine learning algorithms, as well as Vision AI, an AI-powered platform developed with joint venture partner Ainnova Tech Inc. for rapid detection of diabetic retinopathy and other retinal diseases via fundus eye tests. The company, founded in 2017 and headquartered in Las Vegas, Nevada with operations linked to Vilnius, Lithuania, targets healthcare, business optimization, scientific simulations, climate modeling, protein folding analysis, and big data processing across global markets, serving AI developers, enterprises, and healthcare providers. Formerly known as Trend Innovations Holding Inc., it changed its name in July 2023; in late 2024 formed Ai-nova Acquisition Corp. with Ainnova to commercialize its technology portfolio; in March 2024 entered negotiations to acquire a healthcare data interoperability firm for $2 million in cash and stock to bolster revenue and AI services; in June 2025 signed a non-binding letter of intent for a business combination with Ainnova ahead of U.S. FDA meetings for Vision AI clinical trials; in September 2025 announced a strategic shift to biotech partnerships including joint ventures for cell-based therapies like Klotho protein production with Austrianova under Klothonova launched in October 2025, and applied for a corporate name change to reflect its focus on health and longevity advancements.
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders
Avant Brands Announces its Annual General and Special Meeting
Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
Scalable Biotech Manufacturing Unlocks a $14B Market
Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Avant Brands Continues to Strengthen Balance Sheet with $1.77 Million Debt Retirement at $0.935 Per Unit
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards
Avant Brands Reports Audited Fiscal 2025 Results with 19% Recreational Revenue Growth
Avant Brands Announces Timing of Release of Fiscal 2025 Annual Results
Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
Avant Brands Adopts Shareholder Rights Plan
Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival